HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas

He,Jing; Liu,Chaoyang; Wang,Bin; Li,Na; Zuo,Guoqin; Gao,Dewei

doi:10.3892/ijo.2015.3131

HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas

Authors:
- Jing He
- Chaoyang Liu
- Bin Wang
- Na Li
- Guoqin Zuo
- Dewei Gao
View Affiliations

Affiliations: Integrated Surgery Department of South Building of Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: August 25, 2015 https://doi.org/10.3892/ijo.2015.3131
Pages: 1503-1511

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The high-mobility group nucleosome-binding protein-5 (HMGN5) is frequently overexpressed in various malignant cancers. However, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown. In the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome. Potential effects of HMGN5 on tumor growth, apoptosis and invasion were also examined in representative cell lines (IOMM-Lee and CH157) by downregulating HMGN5 with RNA interference (siRNA). We demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade. Statistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence. In addition, downregulation of HMGN5 inhibits IOMM-Lee and CH157 cell proliferation, enhances cell apoptosis and suppresses tumor invasion. Our results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells. Collectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.

View Figures

View References

1	Fathi AR and Roelcke U: Meningioma. Curr Neurol Neurosci Rep. 13:3372013. View Article : Google Scholar : PubMed/NCBI
2	Dubel GJ, Ahn SH and Soares GM: Contemporary endovascular embolotherapy for meningioma. Semin Intervent Radiol. 30:263–277. 2013. View Article : Google Scholar :
3	Walcott BP, Nahed BV, Brastianos PK and Loeffler JS: Radiation Treatment for WHO Grade II and III meningiomas. Front Oncol. 3:2272013. View Article : Google Scholar : PubMed/NCBI
4	Saraf S, McCarthy BJ and Villano JL: Update on meningiomas. Oncologist. 16:1604–1613. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rochman M, Malicet C and Bustin M: HMGN5/NSBP1: A new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 1799:86–92. 2010. View Article : Google Scholar : PubMed/NCBI
6	Shirakawa H, Landsman D, Postnikov YV and Bustin M: NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression. J Biol Chem. 275:6368–6374. 2000. View Article : Google Scholar : PubMed/NCBI
7	Rochman M, Postnikov Y, Correll S, Malicet C, Wincovitch S, Karpova TS, McNally JG, Wu X, Bubunenko NA, Grigoryev S, et al: The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol Cell. 35:642–656. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ji SQ, Yao L, Zhang XY, Li XS and Zhou LQ: Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 31:222012. View Article : Google Scholar : PubMed/NCBI
9	Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, Song G, He Q, Li XS and Zhou LQ: The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 32:931–939. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jiang N, Zhou LQ and Zhang XY: Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. Asian J Androl. 12:709–717. 2010. View Article : Google Scholar : PubMed/NCBI
11	Qu J, Yan R, Chen J, Xu T, Zhou J, Wang M, Chen C, Yan Y and Lu Y: HMGN5: A potential oncogene in gliomas. J Neurooncol. 104:729–736. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wang Q, Wang JY, Zhang XP, Lv ZW, Fu D, Lu YC, Hu GH, Luo C and Chen JX: RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. Carcinogenesis. 34:916–926. 2013. View Article : Google Scholar : PubMed/NCBI
13	Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
14	Soane L and Fiskum G: Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins. J Bioenerg Biomembr. 37:179–190. 2005. View Article : Google Scholar : PubMed/NCBI
15	Basu A, DuBois G and Haldar S: Posttranslational modifications of Bcl2 family members - a potential therapeutic target for human malignancy. Front Biosci. 11:1508–1521. 2006. View Article : Google Scholar
16	Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ and Kuppen PJ: The prognostic value of the apoptosis pathway in colorectal cancer: A review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer. 5:13–29. 2013. View Article : Google Scholar : PubMed/NCBI
17	Murray J and Renslo AR: Modulating caspase activity: Beyond the active site. Curr Opin Struct Biol. 23:812–819. 2013. View Article : Google Scholar : PubMed/NCBI
18	McCracken JM and Allen LA: Regulation of human neutrophil apoptosis and lifespan in health and disease. J Cell Death. 7:15–23. 2014.PubMed/NCBI
19	Vranic A: Caspase-3 and survivin expression in primary atypical and malignant meningiomas. ISRN Neurosci. 2013:6262902013. View Article : Google Scholar : PubMed/NCBI
20	Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H and Sone S: Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res. 62:5967–5973. 2002.PubMed/NCBI
21	Mandara MT, Pavone S, Mandrioli L, Bettini G, Falzone C and Baroni M: Matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in canine and feline meningioma. Vet Pathol. 46:836–845. 2009. View Article : Google Scholar : PubMed/NCBI
22	Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K and Nagao S: Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol. 66:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
23	Kast RE and Halatsch ME: Matrix metalloproteinase-2 and -9 in glioblastoma: A trio of old drugs - captopril, disulfiram and nelfinavir - are inhibitors with potential as adjunctive treatments in glioblastoma. Arch Med Res. 43:243–247. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chamberlain MC, Tsao-Wei DD and Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology. 62:1210–1212. 2004. View Article : Google Scholar : PubMed/NCBI
25	Li G, Zhang H, Liu Y, Kong L, Guo Q and Jin F: Effect of temozolomide on livin and caspase-3 in U251 glioma stem cells. Exp Ther Med. 9:744–750. 2015.PubMed/NCBI
26	Akay C, Thomas C III and Gazitt Y: Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms. Cell Cycle. 3:324–334. 2004. View Article : Google Scholar : PubMed/NCBI
27	Wang Q, Qian J, Wang J, Luo C, Chen J, Hu G and Lu Y: Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
28	Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G and Krex D: A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 20:175–181. 2009. View Article : Google Scholar
29	Andersson U, Malmer B, Bergenheim AT, Brännström T and Henriksson R: Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol. 23:21–27. 2004.PubMed/NCBI